EYEPOINT INC (EYPT)

Health Care · Ophthalmic pharmaceuticals / retinal disease therapeutics · NASDAQ

EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular edema, with the approved product DEXYCU generating minimal revenue.

Themes: ["Ophthalmology / eye disease","Wet AMD / age-related macular degeneration","Diabetic macular edema (DME)","Clinical-stage biopharmaceutical","Drug delivery","Heavily dependent on clinical and commercial success of lead product candidate DURAVYU, which is still in development; failure to successfully complete clinical trials or achieve regulatory approval could materially harm business.","Significant ongoing operating losses and unprofitability; company has accumulated deficit of $1.19 billion and will likely need additional capital; unable to achieve profitability from future operations.","Under DOJ investigation; if unable to reach negotiated resolution, DOJ may commence action that could have material adverse effect on business; even if resolved, may require significant resources for compliance including corporate integrity agreement."]

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.